Sebastian Weis
Overview
Explore the profile of Sebastian Weis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
1838
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schellong P, Joean O, Pletz M, Hagel S, Weis S
Drugs
. 2024 Dec;
85(2):193-214.
PMID: 39720961
The Gram-positive cocci Staphylococcus aureus, Streptococcus spp., and Enterococcus spp. are the most frequent causative organisms of bloodstream infections and infective endocarditis. "Complicated bacteremia" is a term used in S....
2.
Weis S, King I, Vivas W
Cell Host Microbe
. 2024 Oct;
32(10):1648-1650.
PMID: 39389028
Paneth cells located within intestinal crypts support epithelial stem cells and immunity through growth factors and antimicrobial peptides. In this issue of Cell Host & Microbe, Wallaeys et al. report...
3.
Bahrs C, Schonherr C, Panning M, Rose N, Dahne T, Hagel S, et al.
Infection
. 2024 Jul;
53(1):449-455.
PMID: 39033207
Purpose: This study assessed the frequency, clinical significance, and risk factors for Herpes simplex virus (HSV) reactivation in immunocompetent patients with community-acquired pneumonia (CAP). Methods: The study included adult CAP-patients...
4.
von Loeffelholz C, Winkler R, Weigel C, Piskor E, Vivas W, Rauchfuss F, et al.
iScience
. 2024 Jul;
27(7):110133.
PMID: 38984201
Sepsis is a life-threatening condition caused by dysregulated host responses to infection. Myeloid cell accumulation and lymphocyte decline are widely recognized phenomena in septic patients. However, the fate of specific...
5.
Schnizer M, Schellong P, Rose N, Fleischmann-Struzek C, Hagel S, Abbas M, et al.
Clin Microbiol Infect
. 2024 Jun;
30(10):1254-1260.
PMID: 38823452
Background: Current guidelines recommend at least 2 weeks duration of antibiotic therapy (DOT) for patients with uncomplicated Staphylococcus aureus bacteraemia (SAB) but the evidence for this recommendation is unclear. Objectives:...
6.
Thomas-Ruddel D, Bauer M, Moita L, Helbig C, Schlattmann P, Ehler J, et al.
BMJ Open
. 2024 Apr;
14(4):e075158.
PMID: 38653508
Introduction: Sepsis remains the major cause of death among hospitalised patients in intensive care. While targeting sepsis-causing pathogens with source control or antimicrobials has had a dramatic impact on morbidity...
7.
Wu Q, Carlos A, Braza F, Bergman M, Kitoko J, Bastos-Amador P, et al.
EMBO J
. 2024 Mar;
43(8):1445-1483.
PMID: 38499786
Regulatory T (TREG) cells develop via a program orchestrated by the transcription factor forkhead box protein P3 (FOXP3). Maintenance of the TREG cell lineage relies on sustained FOXP3 transcription via...
8.
Giamarellos-Bourboulis E, Aschenbrenner A, Bauer M, Bock C, Calandra T, Gat-Viks I, et al.
Nat Immunol
. 2024 Jan;
25(1):19-28.
PMID: 38168953
Sepsis remains a major cause of morbidity and mortality in both low- and high-income countries. Antibiotic therapy and supportive care have significantly improved survival following sepsis in the twentieth century,...
9.
Bode C, Weis S, Sauer A, Wendel-Garcia P, David S
Crit Care
. 2023 Dec;
27(1):478.
PMID: 38057824
Sepsis, a dysregulated host response to infection characterized by organ failure, is one of the leading causes of death worldwide. Disbalances of the immune response play an important role in...
10.
Hills T, Lorenzi E, Berry L, Shyamsundar M, Al-Beidh F, Annane D, et al.
N Engl J Med
. 2023 Oct;
389(25):2341-2354.
PMID: 37888913
Background: The efficacy of simvastatin in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear. Methods: In an ongoing international, multifactorial, adaptive platform, randomized, controlled trial, we evaluated simvastatin...